PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
Clinical trial NCT00354458 · COMPLETED
Trial details
- NCT number
- NCT00354458
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2006-10-01
- Primary completion
- 2009-07-01
- Enrollment
- 1102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.